Current Report Filing (8-k)
October 28 2019 - 8:31AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 25,
2019
Predictive Oncology Inc.
(Exact name of registrant as specified in charter)
Delaware
|
001-36790
|
83-4360734
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
2915 Commers Drive, Suite 900
Eagan, Minnesota 55121
(Address of principal executive offices)
(651) 389-4800
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240. 13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.01 par value
|
POAI
|
Nasdaq Capital Market
|
|
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
On October 25, 2019, the Certificate of Incorporation
of Predictive Oncology Inc. (the “Company”) was amended to effect a reverse stock split of the outstanding shares of
its common stock at a ratio of one-for-ten (1:10). The amendment was effective October 28, 2019; however, the reverse stock split
will be effective for purposes of the stock market as of the opening of trading on October 29, 2019.
The foregoing summary of the amendment is qualified
in all respects by the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by this
reference.
The reverse stock split of the outstanding shares
of the Company’s common stock, at a ratio of one-for-ten (1:10), will be effective for purposes of the stock market as of
the opening of trading on October 29, 2019.
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
(d)
|
Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 28, 2019
|
PREDICTIVE ONCOLOGY INC.
|
|
|
|
|
|
By:
|
/s/ Bob Myers
|
|
|
|
|
|
|
|
Bob Myers
|
|
|
Chief Financial Officer
|
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Aug 2023 to Aug 2024